BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today a subscription model for its PURE EP™ Platform. Cleveland Clinic—recently ranked as number one in the Nation for cardiology, heart & vascular surgery by U.S. News & World Report1—is first to sign an agreement to acquire the PURE EP™ Platform under the subscription model.
BioSig has made the move to a subscription model so that electrophysiologists and cardiology departments can access the latest features with the ability to customize the rich suite of PURE EP™ software capabilities to suit their needs. The proprietary combination of hardware and software empowers electrophysiologists with real-time, ultra-pure, cardiac signal data, with the potential to improve arrhythmia care and procedures.
“At BioSig, we aspire to be a true partner to the electrophysiology community; constantly advancing our technology to push the boundaries of signal hygiene, analysis, and data application,” said Gray Fleming, Chief Commercial Officer of BioSig. “This subscription model expands access to PURE EP™’s novel and configurable software features as they become available and supports operational expenditure goals by optimizing case-by-case and day-to-day department expenses, removing the burden of ownership and maintenance.”
The agreement follows BioSig’s exhibition at the Heart Rhythm Society 2023 (“HRS 2023”) in May, known for being the largest gathering of heart rhythm professionals worldwide. During the conference, research conceptualized and spearheaded by Cleveland Clinic’s world-class physician faculty highlighted the PURE EP™ Platform’s ability to optimize ablation procedures. The data compared the efficacy of PURE EP™’s unipolar signal guidance to the current standard, the Ablation Index™ for radiofrequency ablation procedures during pulmonary vein isolation. Topline findings from the physician-initiated research revealed a 66% reduction in procedure time while maintaining accuracy, and enhancing precision during PVI.2,3,4
“Cleveland Clinic approached us with the idea to conduct research evaluating the utility and impact of our novel signal applications. A portion of this foundational research was presented at HRS 2023, and we were excited to collaborate with their world-class team of electrophysiologists,” commented Zach Koch, Principal Product Advisor of BioSig. “With a rich history of medical innovation and breakthroughs, Cleveland Clinic has piloted many cutting-edge cardiovascular technologies that are recognized as the standard of care today. We are proud to witness PURE EP™ in use at their clinic and excited to see their commitment to innovation continue as the first subscription-based customer, unlocking the full spectrum of clinical, operational, and economic benefits of the PURE EP™ Platform in a fully customizable package.”
With a comprehensive suite of tools available through the subscription model, the PURE EP™ Platform can deliver the latest developments in electrophysiology to physicians as they emerge, with the flexibility to add enhancements as desired. For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com.
